ReviewThe Lancet. Infectious diseases2017
Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.
Review in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 130 citations in OpenAlex.
- Multicentre outbreak ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Comparing rapid molecular and culture methods for detecting fungal contamination in healthcare environments.Infection control and hospital epidemiology · 2026Observational
- Migratory Preseptal Cellulitis Secondary to Rhinosinusitis Complicated by Left Frontal Subdural Empyema in a Child: A Case Report.Case reports in ophthalmological medicine · 2026Article
- Unravelling azole resistance in fungal pathogens: molecular mechanisms, diagnostic challenges, and therapeutic strategies.World journal of microbiology & biotechnology · 2025Review
- HPathogens (Basel, Switzerland) · 2024Review
- Temporal transcriptional response ofeLife · 2024Article
- Diversity and Distribution of Fungal Infections in Rwanda: High Risk and Gaps in Knowledge, Policy, and Interventions.Journal of fungi (Basel, Switzerland) · 2024Review
- Short Tandem Repeat Genotyping of Medically Important Fungi: A Comprehensive Review of a Powerful Tool with Extensive Future Potential.Mycopathologia · 2024Review
- Proceedings of the second international meeting on endemic mycoses of the Americas (IMEMA) and first international symposium on implantation mycoses (ISIM).Medical mycology · 2024Article
- The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective.Open forum infectious diseases · 2024Review
- Saps1-3 Antigens inInfectious disease reports · 2024Article
- Advancements and challenges in antifungal therapeutic development.Clinical microbiology reviews · 2024Review
- COVID-19-Associated Rhino-Orbital Mucormycosis: Histological and Electron Microscopy Characteristics.Diagnostics (Basel, Switzerland) · 2024Article
- Epidemiology and antifungal susceptibilities of clinically isolatedEpidemiology and infection · 2023Article
- Know the enemy and know yourself: Addressing cryptic fungal pathogens of humans and beyond.PLoS pathogens · 2023Article
- Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis.Journal of clinical immunology · 2023Review
- Evaluation of pre-treated healthcare wastes during COVID-19 pandemic reveals pathogenic microbiota, antibiotics residues, and antibiotic resistance genes against beta-lactams.Environmental research · 2023Article
- Characterization and susceptibility of non-albicansFrontiers in public health · 2023Observational
- Effects of Medicinal Plants on Fungal Community Structure and Function in Hospital Grassplot Soil.Current microbiology · 2022Article
- Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.Membranes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Several high-profile outbreaks have drawn attention to invasive fungal infections (IFIs) as an increasingly important public health problem. IFI outbreaks are caused by many different fungal pathogens and are associated with numerous settings and sources. In the community, IFI outbreaks often occur among people without predisposing medical conditions and are frequently precipitated by environmental disruption. Health-care-associated IFI outbreaks have been linked to suboptimal hospital environmental conditions, transmission via health-care workers' hands, contaminated medical products, and transplantation of infected organs. Outbreak investigations provide important insights into the epidemiology of IFIs, uncover risk factors for infection, and identify opportunities for preventing similar events in the future. Well recognised challenges with IFI outbreak recognition, response, and prevention include the need for improved rapid diagnostic methods, the absence of routine surveillance for most IFIs, adherence to infection control practices, and health-care provider awareness. Additionally, IFI outbreak investigations have revealed several emerging issues, including new populations at risk because of travel or relocation, occupation, or immunosuppression; fungal pathogens appearing in geographical areas in which they have not been previously recognised; and contaminated compounded medications. This report highlights notable IFI outbreaks in the past decade, with an emphasis on these emerging challenges in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.